A Single-arm, Single Center, Phase II Study of RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Disitamab vedotin (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Neuroendocrine carcinoma; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Oct 2023 New trial record